Antibiotic resistance is the greatest threat to cancer patients

  03 February 2024

Investing in new oncology drugs without building up an effective arsenal against infections is a false economy.

Cancer survival rates have never been higher, but nor have the costs of treating cancer, with the escalating price of powerful new drugs being the main driver. Given that the number of clinical trials for new cancer drugs is at an all-time high, and with the vast majority of new drug treatments costing more than $283,000 in the US per patient per year, this trend is expected to continue. But such progress comes at a cost: a lack of investment in other kinds of drugs, particularly antibiotics, often a cancer patient’s last line of defence.

Further reading: Financial Times
Author(s): Manica Balasegaram / GARDP
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed